Abstract Title:

Tetramethylpyrazine, a Promising Drug for Treatment of Pulmonary Hypertension.

Abstract Source:

Br J Pharmacol. 2020 Jan 24. Epub 2020 Jan 24. PMID: 31976548

Abstract Author(s):

Yuqin Chen, Wenju Lu, Kai Yang, Xin Duan, Mengxi Li, Xiuqing Chen, Jie Zhang, Meidan Kuang, Shiyun Liu, Xiongting Wu, Guofa Zou, Chunli Liu, Cheng Hong, Wenjun He, Jing Liao, Chi Hou, Zhe Zhang, Qiuyu Zheng, Jiyuan Chen, Nuofu Zhang, Haiyang Tang, Rebecca R Vanderpool, Ankit A Desai, Franz Rischard, Stephen M Black, Joe G N Garcia, Ayako Makino, Jason X-J Yuan, Nanshan Zhong, Jian Wang

Article Affiliation:

Yuqin Chen


RATIONALE: Tetramethylpyrazine (TMP) is a compound isolated from the traditional Chinese herb ligusticum and the fermented Japanese food natto. TMP can also be chemosynthesized in pharmacy and has long history of proven effects in the treatment of many cardiovascular diseases.

OBJECTIVES: To evaluate the potential therapeutic role of TMP on pulmonary hypertension (PH) both in experimental animal models and in clinical patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).

RESULTS: TMP (100 mg•kg•d) not only prevented rats from developing experimental PH, but also ameliorated PH in three models of established PH: chronic hypoxia- (chronic-HPH), sugen/hypoxia- (SuHx-PH) or monocrotaline-(MCT-PH) induced PH. The therapeutic effect of TMP was likely due to its inhibition of intracellular calcium homeostasis in pulmonary arterial smooth muscle cells. In a small cohort of patients with PAH or CTEPH, oral administration of TMP (100 mg, t.i.d. for 16 weeks) significantly increased the 6-minute walk distance (6MWD, from 385±83 to 446±80 meters; p=0.04 vs baseline, p=0.001 vs control). The 1-minute heart rate recovery (HRR1) was also improved from 13±6 to 19±8 bpm (p=0.03 vs baseline, p=0.001 vs control).

CONCLUSION: Our results suggest that TMP is potentially a novel, potential and inexpensive medication for treatment of PH. Clinical trial is registered with www.chictr.org.cn (ChiCTR-IPR-14005379).

Study Type : Animal Study

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.